Introduction
Acute myeloid leukemia (AML) remains a hematologic malignancy with poor outcome and a high risk for relapse believed to be caused by the survival of leukemic stem cells (LSCs), which are responsible for disease repopulation following treatment [1] . This important implication of LSCs was determined in in vivo assays that allowed engraftment of primary AML specimens into the bone marrow (BM) and spleen of immunocompromised mice. In the non-obese diabetic/severe combined immunodeficient (NOD/ SCID) mouse, researchers determined that LSCs have the ability to self-renew and the capacity to proliferate and differentiate into diverse leukemic cells [2, 3] . Engraftment in the NOD/SCID mouse has also been shown to correlate with poor response to chemotherapy and overall poor patient survival [4, 5] making it a clinically predictive in vivo model. Based on the importance of LSCs, novel approaches that target these cells are being developed and converging with the NOD/SCID mouse assay [6] [7] [8] [9] in efforts to advance desperately needed therapies into the clinic.
We have developed a novel radioimmunotherapy (RIT) strategy targeting CD123 overexpressed on LSCs that we are evaluating in the NOD/SCID mouse AML model. Indium-111 ( 111 In) labeled to CSL360 (CSL Limited, Parkville, Australia), a chimeric IgG 1 specific for CD123, was used to deliver Auger electron irradiation to LSCs.
111
In emits nanometer-micrometer range Auger electrons, which are highly toxic when delivered in close proximity to the DNA [10] . We previously observed that the modification of anti-CD123 antibodies with peptides [CGYGPKKKRKVGG] that harbor a nuclear localization sequence (NLS; underlined) is able to deliver Auger electrons to the nucleus of CD123 þ AML cells and cause significant cytotoxicity in vitro [11] . In addition to Auger electrons, 111 In emits γ-photons used for imaging and we previously reported that 111
In-NLS-CSL360 accumulated specifically at sites of AML engraftment in the BM and spleen of NOD/SCID mice, permitting disease visualization by microSPECT/CT [12] . In order to investigate the potential of 111 In-NLS-CSL360 as a RIT agent for AML, we describe here the results of initial studies to examine its effects on LSCs in engrafted NOD/SCID mice and the utility of this mouse model.
Materials and methods
Radioimmunoconjugates were prepared as previously reported [12] . Primary AML specimens were collected under a protocol (01- Three RIT studies were performed. In the first study, groups of 5 mice with nearly complete leukemic repopulation of the BM at 8 weeks post-engraftment with specimen 090295 were injected intravenously with 16.7 71. [12] . The mass of radioimmunoconjugates injected was 20-27 μg. The effect on human
þ leukemia cells in the BM was measured following imaging at 72 h post-treatment by flow cytometry [12] . of unlabeled CSL360 or received normal saline. At two weeks posttreatment, a complete blood cell count (CBC) was obtained and hemoglobin (Hb) levels were measured. Significant differences (P o0.05) for all studies were tested using an unpaired, two-sided Student's t-test, 1-way ANOVA followed by a Bonferroni multiple comparisons post-test, or log-rank test.
Results and discussion

CD123-targeted Auger electron radiation impairs LSCs in vivo
Specimen 090295 almost completely repopulated the NOD/SCID mouse BM after 8-weeks reaching hCD45 þ /CD123 þ engraftment levels of 84.7%73.5% [12] . This efficiently and reproducibly-engrafting AML specimen serves as a robust initial challenge to provide insight on the efficacy of a LSC-targeted Auger electron RIT approach.
A single dose of radioactivity (16- In-NLS-chIgG 1 (47.2%77.7% vs. 82.6%71.8%, respectively; Po0.0001; Fig. 1A ). This result is encouraging as a rapid molecular response to treatment in AML patients is a favorable characteristic associated with good outcome [13] . These results were supported by biodistribution studies which showed 3-fold greater uptake of 13.872.3%ID/g; P¼0.004) [12] . These are known sites of engraftment of AML in the NOD/SCID mouse. To test the effect on the repopulation capacity of LSCs, transplantations in secondary NOD/SCID mice were conducted. In-NLS-chIgG 1 ( Fig. 1B; P¼0 .04). In-NLS-chIgG 1 treated mice (Fig. 1D) . Under these conditions, the NOD/SCID mouse assay was useful to monitor a rapid (72 h) treatment response to 111 In-NLS-CSL360 and secondary transplantations demonstrated impairment of LSCs. We next determined if non-irradiated and nonengrafted NOD/SCID mice could tolerate similar doses of 111 In-NLS-CSL360 (17-19 MBq; 21-24 μg) to evaluate long-term AML disease. All mice exhibited decreased body weight and had to be sacrificed by day 21. Engraftment of AML into NOD/SCID mice has been instrumental in understanding leukemia biology but these mice have a defect in DNA repair that makes them very sensitive to radiation [14] and we demonstrate how this limitation of the NOD/ SCID assay poses a challenge to assess RIT approaches. In-NLS-CSL360 impairs LSC long term survival and the NOD/SCID mouse assay is suitable to monitor this effect at reduced doses. However, the dose of radioactivity employed in these experiments most likely was insufficient to completely eradicate LSCs, which have inherent resistance properties to radiation [15] and overexpression of proteins involved in DNA repair [16] .
Effect of
The survival of NOD/SCID mice engrafted with sorted In-NLS-chIgG 1 was similar to that for 111 In-NLS-CSL360 treated mice, possibly indicating a beneficial effect of non-targeted radiation. Because the spleen is also an organ for leukemic cell engraftment, which is characterized by gross splenomegaly [11] , we evaluated the leukemic burden by determining the spleen/body weight ratio. All radioimmunoconjugates decreased the spleen/body weight ratio compared to untreated engrafted mice (Fig. 3B) . This was not completely unexpected as the NOD/SCID mouse exhibits very low circulating immunoglobulin levels which cause non-specific sequestration of human IgG 1 by Fc receptors on spleen cells [11] . This would cause leukemia cells to be irradiated by splenic accumulation of In-NLS-chIgG 1 , respectively. The spleen/body weight ratio was increased by 15-fold in mice engrafted with AML compared to sublethally irradiated but non-engrafted mice, demonstrating splenomegaly associated with leukemia involvement. In mice treated with In-NLS-CSL360 and in two cases, was almost completely eradicated from the BM.
111
In-NLS-CSL360 decreased white blood cell (WBC) counts in healthy Balb/c mice only at the highest dose administered (35.8 70.9 MBq; P ¼0.05) with no significant effects compared to mice injected with normal saline at lower doses (Table 1) 21-24 μg) were not tolerated by NOD/SCID mice as discussed, due to the defect in DNA repair [14] . Auger electron RIT with 111 In-NLS-CSL360 offers an unexplored opportunity to specifically deliver ionizing radiation to the critical LSC population in AML. Despite the power of the NOD/SCID mouse AML engraftment assay to predict outcomes in patients with leukemia, there are major challenges for utilizing NOD/SCID mice to study RIT due to its high sensitivity to radiation and low immunoglobulin levels which perturb the pharmacokinetics of radiolabeled antibodies. Nonetheless, our results reveal an effect of 111 In-NLS-CSL360 on decreasing leukemic cells in the BM of AMLengrafted NOD/SCID mice, particularly the CD123 þ cell subpopulation. Studies are in progress to optimize the dose of 111 In-NLS-CSL360 and further evaluate its effectiveness and normal tissue toxicity for RIT of AML in both NOD/SCID mice and in NOD Rag1null IL2rγ null (NRG) mice which have fully functional DNA repair capacity [17] .
